Literature DB >> 16528972

Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage.

Tadeusz Sebzda1, Yousif Saleh, Jakub Gburek, Maria Warwas, Ryszard Andrzejak, Maciej Siewinski, Jerzy Rudnicki.   

Abstract

PURPOSE: Serum cathepsin B (CB), Total Sialic acid (TSA), total sialic acid (TSA) and lipid bound sialic acid (TSA) concentrations more useful than the other markers investigated for detecting different malignancies. Our aim was to investigate the possible correlation between serum CB with TSA, LSA in colorectal carcinoma with pathological stages progressed of the disease.
METHODS: The study was performed on 177 patients (109 patients with colon and 68 patients with rectal) and 50 healthy individuals comprised the control group. Serum CB activity was determined using fluorogenic substrate. Serum TSA and LSA Concentrations were measured according to the method described by Katopodis.
RESULTS: Plasma CB and TSA levels in the tumor group were significantly increased in comparison with the controls group (P < or = 0.0001). No significant differences were observed in LSA level between the tumor group and the controls group. T/N ratios for CB, TSA elevated 2.3-fold, 2.5-fold respectively). LSA 1.8-fold. Serum CB activity, TSA concentrations values in plasma samples of patients were increased significantly with pathological stages progressed (P < or = 0.0001). CB is seen to correlate more strongly with TSA in tumor group (P < or = 0.0001, r= 0.7277) in comparison with controls group. These correlations became more significant as the stage of the disease progressed.
CONCLUSION: The present investigations indicate that CB activity, serum TSA, concentrations are sensitive markers for detecting and earliest diagnosis of colorectal cancer. These markers with other clinical and biochemical criteria may play important metabolic roles in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528972

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  7 in total

Review 1.  Serum sialylation changes in cancer.

Authors:  Zejian Zhang; Manfred Wuhrer; Stephanie Holst
Journal:  Glycoconj J       Date:  2018-04-21       Impact factor: 2.916

2.  Protective role of Withaferin-A on red blood cell integrity during 7,12-dimethylbenz[a]anthracene induced oral carcinogenesis.

Authors:  Shanmugam Manoharan; Kuppusamy Panjamurthy; Pachaiappan Pugalendi; Subramanian Balakrishnan; Kasinathan Rajalingam; Lakshmanan Vellaichamy; Linsa Mary Alias
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-10-25

3.  A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer.

Authors:  Junjie Zhao; Ruihuan Qin; Hao Chen; Yupeng Yang; Wenjun Qin; Jing Han; Xuefei Wang; Shifang Ren; Yihong Sun; Jianxin Gu
Journal:  Clin Proteomics       Date:  2020-09-19       Impact factor: 3.988

Review 4.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Syringic acid may attenuate the oral mucosal carcinogenesis via improving cell surface glycoconjugation and modifying cytokeratin expression.

Authors:  Velu Periyannan; Vinothkumar Veerasamy
Journal:  Toxicol Rep       Date:  2018-10-28

Review 6.  Cysteine cathepsins: from structure, function and regulation to new frontiers.

Authors:  Vito Turk; Veronika Stoka; Olga Vasiljeva; Miha Renko; Tao Sun; Boris Turk; Dušan Turk
Journal:  Biochim Biophys Acta       Date:  2011-10-12

7.  Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.

Authors:  László Herszényi; Fabio Farinati; Romilda Cardin; Gábor István; László D Molnár; István Hritz; Massimo De Paoli; Mario Plebani; Zsolt Tulassay
Journal:  BMC Cancer       Date:  2008-07-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.